Literature DB >> 27820701

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression.

Cecilia Dallavalle, Domenico Albino, Gianluca Civenni, Jessica Merulla, Paola Ostano, Maurizia Mello-Grand, Simona Rossi, Marco Losa, Gioacchino D'Ambrosio, Fausto Sessa, George N Thalmann, Ramon Garcia-Escudero, Andrea Zitella, Giovanna Chiorino, Carlo V Catapano, Giuseppina M Carbone.   

Abstract

Mutations and deletions in components of ubiquitin ligase complexes that lead to alterations in protein turnover are important mechanisms in driving tumorigenesis. Here we describe an alternative mechanism involving upregulation of the microRNA miR-424 that leads to impaired ubiquitination and degradation of oncogenic transcription factors in prostate cancers. We found that miR-424 targets the E3 ubiquitin ligase COP1 and identified STAT3 as a key substrate of COP1 in promoting tumorigenic and cancer stem-like properties in prostate epithelial cells. Altered protein turnover due to impaired COP1 function led to accumulation and enhanced basal and cytokine-induced activity of STAT3. We further determined that loss of the ETS factor ESE3/EHF is the initial event that triggers the deregulation of the miR-424/COP1/STAT3 axis. COP1 silencing and STAT3 activation were effectively reverted by blocking of miR-424, suggesting a possible strategy to attack this key node of tumorigenesis in ESE3/EHF-deficient tumors. These results establish miR-424 as an oncogenic effector linked to noncanonical activation of STAT3 and as a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27820701      PMCID: PMC5127674          DOI: 10.1172/JCI86505

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  39 in total

1.  Impact of normalization on miRNA microarray expression profiling.

Authors:  Sylvain Pradervand; Johann Weber; Jérôme Thomas; Manuel Bueno; Pratyaksha Wirapati; Karine Lefort; G Paolo Dotto; Keith Harshman
Journal:  RNA       Date:  2009-01-28       Impact factor: 4.942

2.  Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer.

Authors:  Alexandra Prtilo; Fredrick S Leach; Regula Markwalder; Andreas Kappeler; Fiona C Burkhard; Marco G Cecchini; Urs E Studer; George N Thalmann
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

3.  ESE3/EHF controls epithelial cell differentiation and its loss leads to prostate tumors with mesenchymal and stem-like features.

Authors:  Domenico Albino; Nicole Longoni; Laura Curti; Maurizia Mello-Grand; Sandra Pinton; Gianluca Civenni; George Thalmann; Gioacchino D'Ambrosio; Manuela Sarti; Fausto Sessa; Giovanna Chiorino; Carlo V Catapano; Giuseppina M Carbone
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 4.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

5.  ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.

Authors:  Paolo Kunderfranco; Maurizia Mello-Grand; Romina Cangemi; Stefania Pellini; Afua Mensah; Veronica Albertini; Anastasia Malek; Giovanna Chiorino; Carlo V Catapano; Giuseppina M Carbone
Journal:  PLoS One       Date:  2010-05-10       Impact factor: 3.240

6.  ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.

Authors:  Nicole Longoni; Manuela Sarti; Domenico Albino; Gianluca Civenni; Anastasia Malek; Erica Ortelli; Sandra Pinton; Maurizia Mello-Grand; Paola Ostano; Gioacchino D'Ambrosio; Fausto Sessa; Ramon Garcia-Escudero; George N Thalmann; Giovanna Chiorino; Carlo V Catapano; Giuseppina M Carbone
Journal:  Cancer Res       Date:  2013-05-16       Impact factor: 12.701

7.  Reduced expression and tumor suppressor function of the ETS transcription factor ESE-3 in prostate cancer.

Authors:  R Cangemi; A Mensah; V Albertini; A Jain; M Mello-Grand; G Chiorino; C V Catapano; G M Carbone
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

Review 8.  STATs in cancer inflammation and immunity: a leading role for STAT3.

Authors:  Hua Yu; Drew Pardoll; Richard Jove
Journal:  Nat Rev Cancer       Date:  2009-11       Impact factor: 60.716

9.  RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer.

Authors:  Gianluca Civenni; Anastasia Malek; Domenico Albino; Ramon Garcia-Escudero; Sara Napoli; Stefano Di Marco; Sandra Pinton; Manuela Sarti; Giuseppina M Carbone; Carlo V Catapano
Journal:  Cancer Res       Date:  2013-09-24       Impact factor: 12.701

10.  Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis.

Authors:  Weiying Zhou; Miranda Y Fong; Yongfen Min; George Somlo; Liang Liu; Melanie R Palomares; Yang Yu; Amy Chow; Sean Timothy Francis O'Connor; Andrew R Chin; Yun Yen; Yafan Wang; Eric G Marcusson; Peiguo Chu; Jun Wu; Xiwei Wu; Arthur Xuejun Li; Zhuo Li; Hanlin Gao; Xiubao Ren; Mark P Boldin; Pengnian Charles Lin; Shizhen Emily Wang
Journal:  Cancer Cell       Date:  2014-04-14       Impact factor: 31.743

View more
  35 in total

Review 1.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

2.  Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells.

Authors:  Davide Genini; Lara Brambilla; Erik Laurini; Jessica Merulla; Gianluca Civenni; Shusil Pandit; Rocco D'Antuono; Laurent Perez; David E Levy; Sabrina Pricl; Giuseppina M Carbone; Carlo V Catapano
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-05       Impact factor: 11.205

3.  Patch-Seq Links Single-Cell Transcriptomes to Human Islet Dysfunction in Diabetes.

Authors:  Joan Camunas-Soler; Xiao-Qing Dai; Yan Hang; Austin Bautista; James Lyon; Kunimasa Suzuki; Seung K Kim; Stephen R Quake; Patrick E MacDonald
Journal:  Cell Metab       Date:  2020-04-16       Impact factor: 27.287

4.  COP1 Acts as a Ubiquitin Ligase for PCDH9 Ubiquitination and Degradation in Human Glioma.

Authors:  Kunlin Zhou; Lei Wang; Zhiyuan Sun; Yuelin Liu; Yufu Zhu; Zhiyi Liu; Bin Zhang; Hengliang Shi
Journal:  Mol Neurobiol       Date:  2022-01-27       Impact factor: 5.590

5.  DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway.

Authors:  Joo-Young Im; Bo-Kyung Kim; Sung-Hoon Yoon; Byoung Chul Cho; Yu Mi Baek; Mi-Jung Kang; Nayeon Kim; Young-Dae Gong; Misun Won
Journal:  Exp Mol Med       Date:  2021-04-15       Impact factor: 8.718

Review 6.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09

7.  Down-regulation of aryl hydrocarbon receptor intensifies carcinogen-induced retinal lesion via SOCS3-STAT3 signaling.

Authors:  Chi-Hao Tsai; Yi Lee; Ching-Hao Li; Yu-Wen Cheng; Jaw-Jou Kang
Journal:  Cell Biol Toxicol       Date:  2019-11-20       Impact factor: 6.691

8.  TGF-β1-induced miR-424 promotes pulmonary myofibroblast differentiation by targeting Slit2 protein expression.

Authors:  Yapei Huang; Yan Xie; Peter W Abel; Peng Wei; Jocelyn Plowman; Myron L Toews; Heather Strah; Aleem Siddique; Kristina L Bailey; Yaping Tu
Journal:  Biochem Pharmacol       Date:  2020-07-24       Impact factor: 5.858

9.  ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.

Authors:  Tianxing Zhou; Jing Liu; Yongjie Xie; Shuai Yuan; Yu Guo; Weiwei Bai; Kaili Zhao; Wenna Jiang; Hongwei Wang; Haotian Wang; Tiansuo Zhao; Chongbiao Huang; Song Gao; Xiuchao Wang; Shengyu Yang; Jihui Hao
Journal:  Gut       Date:  2021-03-05       Impact factor: 31.793

10.  Glucose insult elicits hyperactivation of cancer stem cells through miR-424-cdc42-prdm14 signalling axis.

Authors:  Sushmita Bose Nandy; Alexis Orozco; Rebecca Lopez-Valdez; Rene Roberts; Ramadevi Subramani; Arunkumar Arumugam; Alok Kumar Dwivedi; Viktoria Stewart; Gautham Prabhakar; Stephanie Jones; Rajkumar Lakshmanaswamy
Journal:  Br J Cancer       Date:  2017-10-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.